||Vial: IGF1(Insulin-Like Growth Factor1) Long R3 100mcg. Ampule: 2ml Sterile water for injection.
||Store at room temperature away from heat and direct sunlight pre reconstitution. Refrigerate between 2-8’C post Reconstitution.
||Initial: .5 mcg/kg/day. May increase dose gradually. Max: 5 mcg/kg/day. Maximum period for administration 45 days.
||Acute critical illness due to heart or abdominal surgery, multiple accidental trauma or respiratory failure; active neoplasms, proliferative or pre-proliferative diabetic retinopathy; lactation; patients with closed epiphyses. Intracranial lesions. Patients with Prader-Willi syndrome who are severely obese or have a severe respiratory impairment.
||Monitor thyroid function; benign intracranial hypertension. DM; may require dose reduction in insulin. Pregnancy. Discontinue treatment if there is evidence of tumor growth. Monitoring in patients with scoliosis is recommended due to a risk of progression of scoliosis.
|Adverse Drug Reactions
||Side effects noted are tiredness, feeling of lethargy, head rush or euphoria, itching.
||High doses of corticosteroid may inhibit growth-promoting effects of IGF1LR3.